Dr. Tashko’s Key Clinical Trials
Can 1 or 2 Doses of Zoledronate Prevent Fractures?
Many women in their 50s start thinking about bone health. Osteoporosis medications help high-risk individuals, but what about mild bone loss? A new 10-year study in The New England Journal of Medicine shows that one or two doses of zoledronate significantly reduce fracture risk for a decade. This finding suggests a low-maintenance approach to long-term bone protection.
Published
Cholesterol Mysteries: How ApoB100 and LDL Receptors Bind
Understanding cholesterol metabolism at a molecular level is critical to improving heart health. Recent research offers fresh insights into the relationship between apolipoprotein B100 (apoB100) and low-density lipoprotein (LDL) receptors (LDLR). These findings not only clarify the mechanics of cholesterol metabolism but also open exciting possibilities for future treatments.
Published
Lomitapide: A Bright Hope for Kids with Homozygous Familial Hypercholesterolemia (HoFH)
Living with homozygous familial hypercholesterolemia (HoFH) can feel overwhelming. This rare genetic condition causes dangerously high LDL cholesterol levels from a young age. For children, it means facing the risk of heart disease or stroke far too early in life. However, lomitapide, a medication originally approved for adults in 2012, is showing promising results for kids with HoFH.
Published
How GLP-1 Receptor Agonists Benefit Kidney and Heart Health
GLP-1 receptor agonists have transformed type 2 diabetes care. They lower blood sugar, reduce cardiovascular risks, and now show promise for kidney health. A recent Lancet meta-analysis highlights these benefits, offering insights into how these medications can protect vital organs.
Published
Categorized as Diabetes Care, Dr. Tashko’s Key Clinical Trials, GLP1 agonist, Heart Health, Kidney Health
SURMOUNT-1 Trial: Tirzepatide for Treating Obesity and Preventing Diabetes
Tirzepatide has emerged as a game-changing treatment for obesity and diabetes prevention. This three-year study, an extension of the SURMOUNT-1 trial, highlights its ability to deliver sustained weight loss and significantly lower the risk of type 2 diabetes in individuals with both obesity and prediabetes.
Published
BPROAD Trial: Intensive Blood Pressure Control in Type 2 Diabetes
Managing blood pressure in patients with type 2 diabetes has long been a balancing act. Lowering blood pressure improves heart health, but overly aggressive targets can lead to side effects. This recent study sheds light on the benefits and trade-offs of intensive blood pressure management in a high-risk population.
Published
SUMMIT Trial: Tirzepatide Reduces Heart Failure Risk in Patients with Obesity
The SUMMIT trial investigated how tirzepatide (Mounjaro or Zepbound), a weight-loss medication, affects heart failure with preserved ejection fraction (HFpEF) in patients with obesity. HFpEF, where the heart pumps effectively but struggles to fill properly, is more common in individuals with high body mass index (BMI). Researchers aimed to determine whether tirzepatide could improve cardiovascular outcomes and enhance quality of life for this population.
Published
Can GLP-1s, Semaglutide and Liraglutide Treat Alcohol Use Disorder?
Alcohol Use Disorder (AUD) remains a major global health issue. While psychosocial treatments dominate, medications play a lesser role. Exciting new findings suggest GLP-1 agonists, primarily used for type 2 diabetes and obesity, may help. Among these, semaglutide and liraglutide show the strongest potential for reducing alcohol-related hospitalizations. Though promising, further research is necessary to confirm these results.
Published
Retatrutide: A Promising Breakthrough for Fatty Liver Disease
Fatty liver disease has become a global health crisis, affecting millions worldwide. Now called metabolic dysfunction-associated steatotic liver disease (MASLD), its prevalence has skyrocketed due to rising obesity rates. Retatrutide, a triple hormone receptor agonist, is showing a game-changing potential in reducing liver fat and improving metabolic health.
Published
2024 NLA Expert Clinical Consensus on Apoprotein B (Apo B)
Here I summarize the National Lipid Association’s recent expert consensus, which emphasizes apolipoprotein B (Apo B) as a key tool in managing cardiovascular risk. Apo B, present on atherogenic lipoproteins, gives a more precise assessment of cardiovascular risk than traditional LDL cholesterol (LDL-C) measurements.
Published
GLP-1: A Surprising Friend Against Cancer in Type 2 Diabetes?
New research suggests diabetes drugs known as GLP-1 receptor agonists (GLP-1) might protect against certain cancers. This study focused on type 2 diabetes patients and followed them for 15 years. It’s a surprising finding that could change cancer prevention for diabetes patients.
Published
Semaglutide’s Double Power for Weight Loss and Knee Pain
The study, Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis, explores the impact of weekly semaglutide injections. It focuses on weight loss and pain relief for people with obesity and knee osteoarthritis (OA)
Published